Galera to Present at Two Upcoming Investor Conferences in November
Galera Therapeutics (Nasdaq: GRTX) announced that Mel Sorensen, M.D., CEO, will present at two investor conferences this November. The first event is the Jefferies London Healthcare Conference on November 18, 2021, available on-demand from 8:00 a.m. GMT. The second event is the Piper Sandler Annual Healthcare Conference on November 22, 2021, starting at 10 a.m. ET. Webcasts can be accessed from the investors.galeratx.com page and will be archived for 30 days.
- None.
- None.
MALVERN, Pa., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that Mel Sorensen, M.D., President and Chief Executive Officer, will present at two upcoming investor conferences in November.
| Presentation Details: | |
| Event: | Jefferies London Healthcare Conference |
| Date: | November 18, 2021 |
| Time: | On-demand beginning at 8:00 a.m. GMT (3:00 a.m. ET) |
| Event: | Piper Sandler Annual Healthcare Conference |
| Date: | November 22, 2021 |
| Time: | On-demand beginning at 10 a.m. ET |
Webcasts from the two presentations will be accessible from the Investors page of Galera’s website, investors.galeratx.com. Following the event, archived webcasts will be available on the Galera website for 30 days.
About Galera Therapeutics
Galera Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutic candidates that have the potential to transform radiotherapy in cancer. Galera’s technology consists of selective small molecule dismutase mimetics that are in late-stage development in patients with cancer. Avasopasem manganese (GC4419, also referred to as avasopasem) is in development for radiotherapy-induced toxicities, including SOM in patients with head and neck cancer and esophagitis in patients with lung cancer. Avasopasem has been granted FDA Fast Track and Breakthrough Therapy designations for the reduction of SOM induced by radiotherapy, with or without systemic therapy. Galera’s second dismutase mimetic product candidate, rucosopasem manganese (GC4711, also referred to as rucosopasem), is in clinical-stage development to augment the anti-cancer efficacy of stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer. Galera is headquartered in Malvern, PA. For more information, please visit www.galeratx.com.
Investor Contacts:
Christopher Degnan
Galera Therapeutics, Inc.
610-725-1500
cdegnan@galeratx.com
William Windham
Solebury Trout
646-378-2946
wwindham@soleburytrout.com
Media Contact:
Zara Lockshin
Solebury Trout
646-378-2960
zlockshin@soleburytrout.com
FAQ
What is Galera Therapeutics presenting at the Jefferies London Healthcare Conference?
When is the Piper Sandler Annual Healthcare Conference for Galera Therapeutics?
Where can I find the webcasts for Galera Therapeutics' investor presentations?
How long will the webcasts for Galera's presentations be available?
What does Galera Therapeutics focus on?
